Sei Investments Co. Boosts Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Sei Investments Co. grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,384 shares of the biotechnology company's stock after acquiring an additional 6,411 shares during the period. Sei Investments Co. owned about 0.11% of Blueprint Medicines worth $6,139,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of BPMC. Quantbot Technologies LP purchased a new stake in Blueprint Medicines during the 3rd quarter worth about $108,000. Martingale Asset Management L P grew its position in shares of Blueprint Medicines by 7.6% during the third quarter. Martingale Asset Management L P now owns 15,603 shares of the biotechnology company's stock worth $1,443,000 after buying an additional 1,098 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Blueprint Medicines by 3.4% during the third quarter. Captrust Financial Advisors now owns 17,904 shares of the biotechnology company's stock worth $1,656,000 after buying an additional 582 shares during the period. Verition Fund Management LLC raised its holdings in Blueprint Medicines by 77.5% in the third quarter. Verition Fund Management LLC now owns 9,759 shares of the biotechnology company's stock valued at $903,000 after acquiring an additional 4,260 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Blueprint Medicines in the third quarter valued at approximately $2,323,000.

Insiders Place Their Bets

In other news, insider Ariel Hurley sold 2,250 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the transaction, the insider now directly owns 14,967 shares of the company's stock, valued at $1,496,700. This represents a 13.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company's stock, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,608 shares of company stock worth $3,319,587. Company insiders own 4.21% of the company's stock.

Remove Ads

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded down $5.43 during midday trading on Friday, reaching $81.68. The stock had a trading volume of 1,492,586 shares, compared to its average volume of 742,386. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market cap of $5.22 billion, a P/E ratio of -75.63 and a beta of 0.75. The firm has a fifty day simple moving average of $95.52 and a two-hundred day simple moving average of $93.99. Blueprint Medicines Co. has a 12-month low of $80.08 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BPMC shares. Needham & Company LLC restated a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Stephens restated an "overweight" rating and issued a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Scotiabank initiated coverage on Blueprint Medicines in a research report on Friday, March 7th. They set a "sector outperform" rating and a $150.00 price objective for the company. JMP Securities reissued a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their price target on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and an average target price of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.